Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIT:1BIIB | Italy | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 146.95 | 149.55 | 151.15 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 0.00 | 16:35:09 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 06:00 | UKREG | Dapirolizumab Pegol Phase 3 Data Presented at the American College of.. |
| 14/11/2024 | 16:23 | UKREG | Eisai Receives Positive Opinion from the CHMP in the European Union for.. |
| 30/10/2024 | 23:30 | UKREG | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting.. |
| 29/10/2024 | 22:00 | UKREG | Biogen and Neomorph Announce Multi-Target Research Collaboration to.. |
| 29/10/2024 | 12:00 | UKREG | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer |
| 28/10/2024 | 12:30 | UKREG | Michael McDonnell, Executive Vice President and Chief Financial Officer to.. |
| 27/10/2024 | 00:15 | UKREG | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in.. |
| 24/10/2024 | 11:30 | UKREG | Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease.. |
| 22/10/2024 | 11:30 | UKREG | Biogen Announces Late Breaker and New Data Presentations at American.. |
| 09/10/2024 | 11:30 | UKREG | Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab.. |
1 Year Biogen Chart |
Intraday Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
